StockData
Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc (JAZZ) stock analysis

JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30123% above fair value
$248.24+2.81 (+1.14%)

Close on Nov 11, 2026Market cap $16.11BP/E 80.9Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth2Performance3Health2Dividend0

Weak7 of 30 checks passed

Jazz Pharmaceuticals passes 7 of the 30 checks behind our score; 10 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
2/6
Past performance
3/6
Financial health
2/6
Dividend
0/6

What stands out

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 30.4% of total debt.

  • Guidance raised

    Jazz Pharmaceuticals raised its 2026 Total Revenues outlook on Nov 2, 2026.

  • Growing faster than the industry

    Revenue grew 13.5% over the last twelve months; the Drugs median is 8.0%.

  • Return on equity above the industry

    Jazz Pharmaceuticals's return on equity of 5.1% is above the Drugs median of -58.9%.

What to watch

  • Margin of safety under 20%

    The price is 123% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $248.24 is above our fair value estimate of $111.51.

  • Return on equity under 15%

    Return on equity was 5.1% over the last twelve months and averaged 0.6% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 4.5%, below the 10% that usually covers the cost of capital.

Valuation0/6

  • P/E above its 5-year median

    Jazz Pharmaceuticals's P/E of 80.9 is above its own 5-year median of 17.9.

  • P/E above the industry

    Jazz Pharmaceuticals's P/E of 80.9 is above the Drugs median of 25.1.

  • EV/EBITDA above its 5-year median

    Jazz Pharmaceuticals's EV/EBITDA of 44.2 is above its 5-year median of 23.2.

  • P/B above the industry

    Jazz Pharmaceuticals's price-to-book of 3.84 is above the Drugs median of 2.29.

  • Trading above fair value

    The share price of $248.24 is above our fair value estimate of $111.51.

  • Margin of safety under 20%

    The price is 123% above fair value, so there is no margin of safety.

Growth2/6

  • Revenue growing under 10% a year

    Revenue grew 5.3% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 13.5% over the last twelve months; the Drugs median is 8.0%.

  • Guidance raised

    Jazz Pharmaceuticals raised its 2026 Total Revenues outlook on Nov 2, 2026.

  • Gross margin trend

    This company does not report gross profit.

Past performance3/6

  • Return on equity under 15%

    Return on equity was 5.1% over the last twelve months and averaged 0.6% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 4.5%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Jazz Pharmaceuticals's return on equity of 5.1% is above the Drugs median of -58.9%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was 4.4% over the last twelve months, against a 5-year average of -0.1%.

  • Net margin above the industry

    Jazz Pharmaceuticals's net margin of 4.4% is above the Drugs median of -53.0%.

Financial health2/6

  • High debt

    Debt is 133% of shareholders' equity, above the 40% we consider low.

  • Debt rising against equity

    Debt to equity rose from 57.2% five years ago to 133%.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 30.4% of total debt.

  • Interest coverage

    Interest expense is not reported separately.

  • Short-term assets cover short-term debts

    Current assets are 1.82 times current liabilities.

  • Bankruptcy risk in the grey zone

    The Altman Z-score is 2.01; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Jazz Pharmaceuticals has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$111.51

The share price is 123% above this estimate.

20%+ below
Near fair value
20%+ above
$248.24Price$111.51Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E21.5×17.9×25.1×$65.8940%
EV/EBITDA20.2×23.2×17.1×$90.6735%
P/B2.4×2.5×2.3×$153.1510%
Earnings power7.6% cost of equity––$254.0115%
Fair value$111.51100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 17.9
  • Drugs median 25.1

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$186.33M
Value traded per 1% price move
$123.24M

Downside

Low risk

Typical loss in a bad month
12.3%
Volatility (annualized)
39%
Sharpe ratio, 1 year
2.12
Beta to the S&P 500 (5Y)
0.54

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Operating margin

-10.1%−26.1 pts over 5 years

Net margin

-8.3%−18.4 pts over 5 years

See a number that looks wrong?